Trial Oversight Spotlight #10: Matthew Hersch & Stephen Crow
In this episode:
In this conversation, Tom, Matthew, and Stephen discuss the complexities of governance and oversight in clinical trials, focusing on the vendor management lifecycle. They explore the importance of building strong relationships with CROs, the common mistakes made during vendor selection, and the significance of communication and transparency. The discussion also touches on contract negotiation, budgeting, and future trends in vendor management, emphasising the need for a win-win approach in these partnerships.
Key points:
- Governance in clinical trials involves multiple layers of oversight
- Building trust with CROs is essential for successful partnerships
- Vendor management requires a structured lifecycle approach
- Effective communication can prevent misunderstandings and issues
- A risk-based approach is crucial for vendor qualification
- Future trends include increased technology integration in vendor management
Time stamps:
- – Intros
- – Critical elements of selection process
- – Contract & Negotiations
- – Qualification
- – Vendor onboarding Services
- – Protocol finalisation
Guest Bio
Matthew Hersch & Stephen Crow
Founders of BlueGreen Clinical
With 20 years in Clinical Operations at a pioneering cannabinoid biotech, Matthew Hersch and Stephen Crow guided its growth from startup to mid-sized pharma. Their hands-on experience spans trial management, CRO oversight, team building, and GCP inspections.
In 2023, they founded BlueGreen Clinical to help biotechs build strong Clinical Operations foundations, sharing hard-won insights from their journey.
Host Bio
Tom is running the Trial Oversight Spotlight Interview Series where he meets with a variety of colleagues working in clinical research. They discuss a selection of the most important topics and decisions that are currently being navigated by all types of organisations delivering research.
Tom has spent over a decade in Clinical Trials Operations and Quality Assurance and has experienced the impact that suboptimal vendor oversight and vendor non-compliance can have on the quality of clinical trials. Mayet is the solution to fix this.